MannKind (NASDAQ: MNKD) Expected to Post $16.08M Quarterly Sales


MannKind (NASDAQ: MNKD) is expected to release $16.08 million in sales for this ongoing quarter by equities analysts on 5th May. They have $16.24 million lowest estimates and $16.95 million highest. The firm posted $16.24 million in sales last year in this quarter, indicating a 1% negative annualized growth rate.

On Monday, the company started from $4.15 with a market cap being $1.03 billion. Their lowest in 1 year is $0.91 while the highest is $6.25. They have a -19.78 PE ratio and 2.28 beta. Their 50 day rolling average is $4.42 while the 200 day is $3.25.

According to their 25th February report, they had a quarterly EPS of $0.06, missing the $0.03 consensus estimate by roughly $0.03. Their quarterly revenue was $18.44 million that exceeded the $16.13 estimate.

Market Undertakings of MNKD Stock

Zacks upped the rating of MNKD shares to ‘hold’ from ‘sell’. Oppenheimer reassigned the rating of ‘buy’ and allotted it a price objective of $7. HC Wainwright promoted it to $6.5 from $2.50. SVB Leerink increased it to $5 from $3 and gave a rating of ‘outperform’. BTIG Research lifted it to $8 from $ and gave a rating of ‘buy’. The company has the consensus ‘buy’ recommendation with a $5.70 price objective.

Manufacturers LIC upgraded their holdings on MannKind stock by almost 2% and own shares priced at $420,000. Cambridge Research Advisors promoted their stake by nearly 7.4% and own shares valued at $126,000. Hunter Investment Management lifted their position by approximately 23.9%, owning $49,000 worth shares. High Tower upped their position by roughly 29.5% and own shares priced at $43,000. Virtu Financial promoted their stake by nearly 13% and their own shares valued at $145,000. Hedge funds and institutional investors own 29.60% MannKind stock.

Mannkind happens to be a biopharmaceutical firm which deals with the selling and development of endocrine and diseases of lungs across the US.

Previous articleHow he survived 18 years in solitary confinement
Next articleJrue Holiday Agrees To Extend Bucks’ Stay By Four Years